

ANNUAL REPORT

Accelerating
Diagnosis,
Treatments,
and a Cure for
Celiac Disease

ACCELERATING RESEARCH

Strategic investments in cutting-edge biomedical research and patient engagement to advance the pursuit of treatments and a cure for celiac disease.

PROMOTING EDUCATION

Outreach to patients and healthcare providers has improved the diagnostic rate for celiac disease. Focused investments continue to close the gap and end the needless suffering of millions.

ADVOCACY

Committed to being the worldwide voice of the celiac community before key policy makers in Congress and federal research and regulatory agencies.

Driving Innovation —



iCureCeliac® is the USA's largest public patient registry for celiac disease.



iQualifyCeliac is the only patient-driven celiac disease clinical trial and study recruitment screening tool.



Encouraging the brightest minds in research to focus on finding treatments and a cure for celiac disease.

Impacting Patients –



6.5M CELIAC.ORG



2,000 COMMUNITY
FUNDRAISING
PARTICIPANTS
2018-2019



3,000 ATTENDEES
GLUTEN-FRE
EXPO
annually

Expanding Reach in 2019 ————

House Appropriations Subcommittee testimony by CEO Marilyn G. Geller for dedicated **National Institutes of Health (NIH) funding for celiac disease research**.

Patient-Centered Outcomes Research Institute (PCORI) National Patient Engagement Advisory Panel appointment of Marilyn G. Geller, CEO.

NASPGHAN and Children's National partnership to create the **Celiac Disease Management Plan** to standardize federally-sanctioned accommodations in US schools.

Advancing Therapeutic Treatment Development

iCureCeliac® empowers patients to share their medical information and experiences to shape the future of celiac disease research.



iQualifyCeliac screening tool speeds participation in clinical trials and studies to advance the development of better treatments and a cure for celiac disease.

NUMBER OF CLINICAL TRIALS recruited for in 2018-2019

Funding the **Young Investigator Research Grant Award**, medical education conferences at leading institutions, research studies, and technology innovation including the MedAboutData Hackathon for early diagnosis of celiac disease.

\$850,000 PUNI

FUNDING OF RESEARCH AND CONFERENCES

Educating Providers to Improve Care -

NASPGHAN Clinical Guide for Pediatric Celiac Disease assists physicians in the diagnosis and management of celiac disease.

15,000 PHYSICIA EDUCATE since 2017

Celiac Disease and Psychological Health Program partnership with Children's National educates medical and mental health providers on diagnosing celiac disease and its psychological impact.

PROVIDERS
EDUCATED
since 2016

Celiac Disease Residency Training Program at the Keck School of Medicine of USC trains new physicians in the recognition and treatment of celiac disease.

RESIDENTS
EDUCATED
since 2017

Giving Voice to the Celiac Community -

The **Patient Advocate Program** prepares participants to engage in celiac disease research and public advocacy.

1,300 PARTICIPANTS
since 2016

Collaboration with advocacy coalition partners on **federal initiatives to support patient protections** for autoimmune disease.

2018-2019 **EXECUTED**initiatives

Partnered with Congressmen Tim Ryan and Tom Cole to introduce the **Gluten in Medicine Disclosure Act** for easier identification of gluten in prescription drugs.

22,000



2018 **FINANCIALS**

ASSETS

Cash and Cash Equivalents	\$ 1,672,924
Contributions Receivable	\$ 92,104
Accounts Receivable	\$ 145,950
Prepaid Expenses	\$ 4,430
Investment in Partnership	\$ 37,450
Deposits	\$ 8,425
Property and Equipment	\$ 119,761

Total Assets \$ 2,081,044

LIABILITIES

Accounts Payable\$ 16,843Accrued Vacation\$ 44,234Unearned Revenue\$ 157,793

Total Liabilities \$218,870

NET ASSETS

Unrestricted \$ 1,862,174

Total Liabilities and Net Assets \$2,081,044

OPERATING SUPPORT

Contributions and Grants \$ 1,030,976 Annual Meeting \$ 69,306 Gifts in Kind \$ 372,736 Sponsorships, Program Income \$ 662,289 and Special Events

Total Revenue \$2,135,307

OPERATING EXPENSES

Program Expenses\$ 1,318,016Management and General\$ 66,430Fundraising\$ 50,334

Total Expenses \$1,434,780

Change in Net Assets \$700,527